Sudarshan Pharma

Which are the latest news on Sudarshan Pharma?

Why is Sudarshan Pharma Industries Ltd falling/rising?

As of 05-Sep, Sudarshan Pharma Industries Ltd's stock price has risen to 39.42, reflecting a 1.03% increase. This growth is driven by strong historical performance, positive trading indicators, and increased investor participation, significantly outperforming the Sensex.

As of 05-Sep, Sudarshan Pharma Industries Ltd is experiencing a rise in its stock price, currently at 39.42, reflecting an increase of 0.4 (1.03%). This upward movement can be attributed to several factors. <BR><BR>Firstly, the stock has shown strong performance over the past month, with a notable increase of 15.26%, significantly outperforming the Sensex, which declined by 2.44% during the same period. Year-to-date, the stock has risen by 43.09%, while the Sensex has fallen by 10.21%, indicating a robust relative performance. Additionally, over the past three years, Sudarshan Pharma has achieved an impressive growth of 369.29%, compared to the Sensex's 16.59%.<BR><BR>Today's trading activity further supports the stock's rise, as it has outperformed its sector by 1.3%. The stock is also trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, which is a positive technical indicator. Furthermore, there has been a significant increase in investor participation, with delivery volume rising by 51.8% against the 5-day average, suggesting growing interest and confidence among investors.<BR><BR>Overall, the combination of strong historical performance, positive trading indicators, and increased investor participation contributes to the rising stock price of Sudarshan Pharma Industries Ltd.

Who are in the management team of Sudarshan Pharma?

The management team of Sudarshan Pharma includes Hemal V Mehta (Managing Director), Sachin V Mehta (Joint Managing Director & CFO), Ujwala Vilas Salvi (Director), Subhash Goverdhandasji Bissa (Director), and Rushabh Prashant Patil (Additional Director).

The management team of Sudarshan Pharma includes the following individuals:<BR><BR>1. **Hemal V Mehta** - Managing Director<BR>2. **Sachin V Mehta** - Joint Managing Director & CFO<BR>3. **Ujwala Vilas Salvi** - Director<BR>4. **Subhash Goverdhandasji Bissa** - Director<BR>5. **Rushabh Prashant Patil** - Additional Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

What does Sudarshan Pharma do?

Sudarshan Pharma Industries Ltd is a micro-cap company in the specialty chemicals industry, with net sales of ₹174 Cr and a net profit of ₹6 Cr as of June 2026. It was incorporated in 2008 and has a market cap of ₹986 Cr.

Overview: <BR>Sudarshan Pharma Industries Ltd operates in the specialty chemicals industry and is categorized as a micro-cap company.<BR><BR>History: <BR>The company was initially incorporated in 2008 as "Sudarshan Specialty Chemsolve Private Limited" and changed its name to "Sudarshan Pharma Industries Private Limited" in December 2016. The most recent quarterly results report net sales and net profit for June 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 174 Cr (Quarterly Results - Jun 2026) <BR>Net Profit: 6 Cr (Quarterly Results - Jun 2026) <BR>Market Cap: INR 986 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 39.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 1.83 <BR>Return on Equity: 15.03% <BR>Price to Book: 6.48 <BR><BR>Contact Details: <BR>No Company Details Available <BR>Registrar Address: Not available.

Who are the peers of the Sudarshan Pharma?

Sudarshan Pharma's peers include Excel Industries, Platinum Industries, Jyoti Resins, Sunshield Chemicals, Amal, Indo Amines, Gem Aromatics, Fairchem Organic, and Valiant Organics. Sudarshan Pharma has the highest 1-year return at 16.78%, while Gem Aromatics has the lowest at -39.13%.

Peers: The peers of Sudarshan Pharma are Excel Industries, Platinum Industr, Jyoti Resins, Sunshield Chem., Amal, Indo Amines, Gem Aromatics, Fairchem Organic, Valiant Organics.<BR><BR>Quality Snapshot: Excellent management risk is observed at Jyoti Resins, while Average management risk is found at Excel Industries, Platinum Industr, Sunshield Chem., Sudarshan Pharma, Amal, Indo Amines, and Fairchem Organic, and Below Average management risk is noted at Gem Aromatics and Valiant Organics. Growth is rated as Excellent for Sudarshan Pharma, Good for Jyoti Resins and Amal, and Below Average for Excel Industries, Platinum Industr, Sunshield Chem., Indo Amines, Fairchem Organic, Gem Aromatics, and Valiant Organics. Capital Structure is rated as Excellent for Excel Industries and Platinum Industr, Average for Sunshield Chem., Amal, and Valiant Organics, Below Average for Sudarshan Pharma, Indo Amines, and Gem Aromatics, and Good for Fairchem Organic.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Sudarshan Pharma at 16.78%, while the peer with the lowest is Gem Aromatics at -39.13%. Sudarshan Pharma's return is significantly higher than the lowest peer. Additionally, Indo Amines, Gem Aromatics, and Fairchem Organic have negative six-month returns.

How big is Sudarshan Pharma?

As of 31st August, Sudarshan Pharma Industries Ltd has a market capitalization of 986.00 Cr, with net sales of 732.22 Cr and a net profit of 25.13 Cr over the latest four quarters.

As of 31st August, Sudarshan Pharma Industries Ltd has a market capitalization of 986.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported net sales of 732.22 Cr and a net profit of 25.13 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 131.48 Cr and total assets of 402.41 Cr.

Should I buy, sell or hold Sudarshan Pharma Industries Ltd?

Are Sudarshan Pharma Industries Ltd latest results good or bad?

Sudarshan Pharma Industries Ltd's latest results show strong revenue growth of 36.72% year-on-year, reaching ₹220.92 crores, and a net profit increase of 146.10% quarter-on-quarter. However, declining operating margins and rising interest expenses indicate operational challenges and high financial leverage, raising concerns about the sustainability of this performance.

Sudarshan Pharma Industries Ltd's latest results present a mixed picture. On one hand, the company achieved impressive revenue growth of 36.72% year-on-year, reaching ₹220.92 crores in Q4 FY26. This marks the highest quarterly revenue in its recent history, indicating strong demand for its specialty chemical products. Additionally, net profit saw a significant increase of 146.10% quarter-on-quarter, amounting to ₹10.73 crores.<BR><BR>However, despite these positive revenue and profit figures, the company is facing notable operational challenges. The operating margin has decreased to 9.14%, down from 9.85% in the same quarter last year, suggesting that rising input costs or pricing pressures are impacting profitability. Furthermore, the company's interest expenses have surged to ₹7.53 crores, the highest recorded, reflecting a substantial debt burden that constrains financial flexibility.<BR><BR>Overall, while the revenue growth is commendable, the margin compression and high financial leverage raise concerns about the sustainability of this performance. Investors should consider these factors when evaluating the company's results.

When is the next results date for Sudarshan Pharma Industries Ltd?

The next results date for Sudarshan Pharma Industries Ltd is April 30, 2026.

The next results date for Sudarshan Pharma Industries Ltd is scheduled for April 30, 2026.

Is Sudarshan Pharma technically bullish or bearish?

As of December 4, 2025, Sudarshan Pharma's technical trend is mildly bearish, with indicators like the MACD and moving averages supporting this outlook, despite some mild bullishness from the KST and a neutral RSI.

As of 4 December 2025, the technical trend for Sudarshan Pharma has changed from bearish to mildly bearish. The current stance is mildly bearish, driven by the weekly MACD indicating bearish momentum and the moving averages also reflecting a mildly bearish outlook. The Bollinger Bands confirm this sentiment on both weekly and monthly time frames. Although the KST shows mild bullishness weekly, it is not strong enough to counter the overall bearish indicators. The RSI shows no signal, indicating a lack of momentum in either direction. Overall, the technical indicators suggest a cautious approach given the prevailing mildly bearish conditions.

Is Sudarshan Pharma overvalued or undervalued?

As of November 10, 2025, Sudarshan Pharma is considered very expensive and overvalued with a PE ratio of 42.23, significantly underperforming the market with a 36.43% decline year-to-date, compared to its peers like Sun Pharma and Divi's Lab.

As of 10 November 2025, Sudarshan Pharma's valuation grade has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently considered overvalued based on its key financial ratios, including a PE ratio of 42.23, an EV to EBITDA of 22.69, and a PEG ratio of 1.01. These figures suggest that the stock is trading at a premium compared to its earnings and growth potential.<BR><BR>In comparison to its peers, Sudarshan Pharma's valuation stands out, with Sun Pharma at a PE of 35.15 and Divi's Lab at a staggering 71.55, both categorized as very expensive. Other competitors like Cipla and Dr. Reddy's Labs are considered attractive, with PE ratios of 22.45 and 17.33, respectively. The stark contrast in valuation metrics highlights Sudarshan Pharma's overvaluation. Additionally, the company's stock has underperformed significantly year-to-date, down 36.43%, compared to a 6.91% gain in the Sensex, reinforcing the notion that it is overvalued in the current market environment.

How has been the historical performance of Sudarshan Pharma?

Sudarshan Pharma has shown consistent growth from March 2022 to March 2025, with net sales increasing from 357.09 Cr to 505.05 Cr, and profit after tax rising from 5.25 Cr to 15.95 Cr, alongside significant improvements in operating cash flow and total assets. The company's financial performance reflects a strong upward trend in sales, profitability, and asset growth.

Answer:<BR>The historical performance of Sudarshan Pharma shows a consistent growth trajectory in net sales and profits over the past four years, culminating in the fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Sudarshan Pharma's net sales increased from 357.09 Cr in March 2022 to 505.05 Cr in March 2025, reflecting a robust growth trend. Total operating income followed a similar pattern, rising from 357.09 Cr in March 2022 to 505.05 Cr in March 2025. The company's operating profit (PBDIT) also saw significant growth, climbing from 11.38 Cr in March 2022 to 42.44 Cr in March 2025, while the profit before tax rose from 7.14 Cr to 21.63 Cr in the same period. Consequently, profit after tax increased from 5.25 Cr in March 2022 to 15.95 Cr in March 2025, indicating improved profitability. The company's total assets grew substantially from 137.52 Cr in March 2022 to 402.41 Cr in March 2025, driven by increases in both current and non-current assets. Total liabilities also rose, from 137.52 Cr to 402.41 Cr, primarily due to higher short-term borrowings, which increased from 25.65 Cr to 160.27 Cr. Cash flow from operating activities improved significantly, moving from a negative 3 Cr in March 2022 to a positive 35 Cr in March 2025, highlighting enhanced operational efficiency. Overall, Sudarshan Pharma's financial performance demonstrates a strong upward trend in sales, profitability, and asset growth over the analyzed period.

Who are the top shareholders of the Sudarshan Pharma?

The top shareholders of Sudarshan Pharma include promoter Sachin Vasantrai Mehta with 27.51%, 11 Foreign Institutional Investors holding 18.45%, and public shareholder Multitude Growth Funds Limited at 5.52%. Individual investors own 18.18% of the shares, with no pledged promoter holdings or mutual fund investments.

The top shareholders of Sudarshan Pharma include the promoters, with Sachin Vasantrai Mehta holding the highest stake at 27.51%. Additionally, 11 Foreign Institutional Investors (FIIs) collectively hold 18.45% of the shares. The highest public shareholder is Multitude Growth Funds Limited, which owns 5.52%. Individual investors also have a significant presence, holding 18.18% of the company's shares. There are no pledged promoter holdings, and no mutual funds are currently invested in the company.

Has Sudarshan Pharma declared dividend?

Sudarshan Pharma Industries Ltd has declared a 3% dividend, amounting to 0.3 per share, with an ex-date of August 25, 2023. Despite this, the dividend yield is 0%, and the total returns over the last six months are -26.55%, while the past year shows a significant gain of 367.73%.

Sudarshan Pharma Industries Ltd has declared a 3% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 3%<BR>- Amount per share: 0.3<BR>- Ex-date: 25 Aug 23<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>Over the last 6 months, the price return was -26.55%, with a dividend return of 0%, resulting in a total return of -26.55%.<BR><BR>In the past year, the price return was 367.73%, with a dividend return of 0%, leading to a total return of 367.73%.<BR><BR>Over 2 years, the price return was 360.75%, with a dividend return of 0%, resulting in a total return of 360.75%.<BR><BR>For the 3-year period, there was no price return, no dividend return, and thus a total return of 0.0%.<BR><BR>In the last 4 years, the price return was 0%, with a dividend return of 0%, resulting in a total return of 0.0%.<BR><BR>Over the last 5 years, there was no price return, no dividend return, leading to a total return of 0.0%.<BR><BR>Overall, while Sudarshan Pharma has declared a dividend, the dividend yield remains at 0%. The total returns show significant gains over the past year and two years, but recent performance over the last six months has been negative.